NasdaqGS:IART

Stock Analysis Report

NOT FOR DISTRIBUTION
Header cover image

Integra LifeSciences Holdings

Market Cap

US$6.1b

Last Updated

2021/08/01 22:13 UTC

Data Sources

Company Financials +

Executive Summary

Integra LifeSciences Holdings Corporation develops, manufactures, and markets surgical implants and medical instruments for use in neurosurgery, extremity reconstruction, orthopedics, and general surgery. More Details


Snowflake Analysis

Good value with acceptable track record.


Similar Companies

Share Price & News

How has Integra LifeSciences Holdings's share price performed over time and what events caused price changes?


Latest Share Price and Events

Stable Share Price: IART is less volatile than 75% of US stocks over the past 3 months, typically moving +/- 3% a week.

Volatility Over Time: IART's weekly volatility (3%) has been stable over the past year.


Market Performance


7 Day Return

5.7%

IART

1.7%

US Medical Equipment

-0.4%

US Market


1 Year Return

51.6%

IART

29.8%

US Medical Equipment

35.9%

US Market

Return vs Industry: IART exceeded the US Medical Equipment industry which returned 29.9% over the past year.

Return vs Market: IART exceeded the US Market which returned 35.9% over the past year.


Shareholder returns

IARTIndustryMarket
7 Day5.7%1.7%-0.4%
30 Day3.6%3.7%-0.3%
90 Day-2.3%6.4%3.1%
1 Year51.6%51.6%30.7%29.8%38.0%35.9%
3 Year14.2%14.2%74.9%70.7%62.9%52.7%
5 Year70.4%70.4%147.9%136.4%121.3%96.9%

Long-Term Price Volatility Vs. Market

How volatile is Integra LifeSciences Holdings's share price compared to the market and industry in the last 5 years?


Simply Wall St News

Valuation

Is Integra LifeSciences Holdings undervalued compared to its fair value and its price relative to the market?

32.5%

Undervalued compared to fair value


Share Price vs. Fair Value

Below Fair Value: IART ($72.39) is trading below our estimate of fair value ($107.22)

Significantly Below Fair Value: IART is trading below fair value by more than 20%.


Price To Earnings Ratio

PE vs Industry: IART is good value based on its PE Ratio (29.7x) compared to the US Medical Equipment industry average (49x).

PE vs Market: IART is poor value based on its PE Ratio (29.7x) compared to the US market (18.1x).


Price to Earnings Growth Ratio

PEG Ratio: IART is poor value based on its PEG Ratio (1.9x)


Price to Book Ratio

PB vs Industry: IART is good value based on its PB Ratio (3.9x) compared to the US Medical Equipment industry average (4.5x).


Future Growth

How is Integra LifeSciences Holdings forecast to perform in the next 1 to 3 years based on estimates from 13 analysts?

15.4%

Forecasted annual earnings growth


Earnings and Revenue Growth Forecasts


Analyst Future Growth Forecasts

Earnings vs Savings Rate: IART's forecast earnings growth (15.4% per year) is above the savings rate (2%).

Earnings vs Market: IART's earnings (15.4% per year) are forecast to grow faster than the US market (15% per year).

High Growth Earnings: IART's earnings are forecast to grow, but not significantly.

Revenue vs Market: IART's revenue (6.3% per year) is forecast to grow slower than the US market (9.2% per year).

High Growth Revenue: IART's revenue (6.3% per year) is forecast to grow slower than 20% per year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: IART's Return on Equity is forecast to be low in 3 years time (14.4%).


Past Performance

How has Integra LifeSciences Holdings performed over the past 5 years?

19.5%

Historical annual earnings growth


Earnings and Revenue History

Quality Earnings: IART has high quality earnings.

Growing Profit Margin: IART became profitable in the past.


Past Earnings Growth Analysis

Earnings Trend: IART's earnings have grown by 19.5% per year over the past 5 years.

Accelerating Growth: IART has become profitable in the last year, making the earnings growth rate difficult to compare to its 5-year average.

Earnings vs Industry: IART has become profitable in the last year, making it difficult to compare its past year earnings growth to the Medical Equipment industry (30.1%).


Return on Equity

High ROE: IART's Return on Equity (13.1%) is considered low.


Financial Health

How is Integra LifeSciences Holdings's financial position?


Financial Position Analysis

Short Term Liabilities: IART's short term assets ($1.0B) exceed its short term liabilities ($318.8M).

Long Term Liabilities: IART's short term assets ($1.0B) do not cover its long term liabilities ($1.8B).


Debt to Equity History and Analysis

Debt Level: IART's debt to equity ratio (102.3%) is considered high.

Reducing Debt: IART's debt to equity ratio has increased from 88.8% to 102.3% over the past 5 years.

Debt Coverage: IART's debt is not well covered by operating cash flow (19.3%).

Interest Coverage: IART's interest payments on its debt are well covered by EBIT (5x coverage).


Balance Sheet


Dividend

What is Integra LifeSciences Holdings's current dividend yield, its reliability and sustainability?


Dividend Yield vs Market

Notable Dividend: Unable to evaluate IART's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

High Dividend: Unable to evaluate IART's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if IART's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if IART's dividend payments have been increasing.


Current Payout to Shareholders

Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of IART's dividend in 3 years as they are not forecast to pay a notable one for the US market.


Next Steps

Management

How experienced are the management team and are they aligned to shareholders interests?

3.8yrs

Average management tenure


CEO

Pete Arduini (56 yo)

9.5yrs

Tenure

US$7,740,699

Compensation

Mr. Peter J. Arduini, also known as Pete, has been the Chief Executive Officer of Integra LifeSciences Holdings Corporation (formerly, Integra LifeSciences Corporation) since January 3, 2012 and has been i...


CEO Compensation Analysis

Compensation vs Market: Pete's total compensation ($USD7.74M) is about average for companies of similar size in the US market ($USD6.51M).

Compensation vs Earnings: Pete's compensation has been consistent with company performance over the past year.


Leadership Team

Experienced Management: IART's management team is considered experienced (3.8 years average tenure).


Board Members

Experienced Board: IART's board of directors are considered experienced (8.7 years average tenure).


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: IART insiders have only sold shares in the past 3 months.


Recent Insider Transactions

Ownership Breakdown

Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.


Top Shareholders

Company Information

Integra LifeSciences Holdings Corporation's company bio, employee growth, exchange listings and data sources


Key Information

  • Name: Integra LifeSciences Holdings Corporation
  • Ticker: IART
  • Exchange: NasdaqGS
  • Founded: 1989
  • Industry: Health Care Equipment
  • Sector: Healthcare
  • Market Cap: US$6.123b
  • Shares outstanding: 84.58m
  • Website: https://www.integralife.com

Number of Employees


Location

  • Integra LifeSciences Holdings Corporation
  • 1100 Campus Road
  • Princeton
  • New Jersey
  • 8540
  • United States

Listings


Biography

Integra LifeSciences Holdings Corporation develops, manufactures, and markets surgical implants and medical instruments for use in neurosurgery, extremity reconstruction, orthopedics, and general surgery. ...


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2021/08/01 22:13
End of Day Share Price2021/07/30 00:00
Earnings2021/06/30
Annual Earnings2020/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.